CL2013000787A1 - Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras. - Google Patents

Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras.

Info

Publication number: CL2013000787A1
Authority: CL; Chile
Prior art keywords: visceral; acute; useful; treatment; pharmaceutical composition
Prior art date: 2010-09-22

Application number

CL2013000787A

Other languages

English (en)

Inventor

Stefan Schunk

Melanie Reich

Ruth Jostock

Vry Jean De

Christa Kneip

Tieno Germann

Michael Engels

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-22

Filing date

2013-03-21

Publication date

2013-09-23

2013-03-21 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2013-09-23 Publication of CL2013000787A1 publication Critical patent/CL2013000787A1/es

Links

KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
102000010183 Bradykinin receptor Human genes 0.000 title 1
108050001736 Bradykinin receptor Proteins 0.000 title 1
201000004624 Dermatitis Diseases 0.000 title 1
230000001154 acute effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000004296 neuralgia Diseases 0.000 title 1
208000021722 neuropathic pain Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000009278 visceral effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)

CL2013000787A 2010-09-22 2013-03-21 Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras. CL2013000787A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10010200		2010-09-22

Publications (1)

Publication Number	Publication Date
CL2013000787A1 true CL2013000787A1 (es)	2013-09-23

Family

ID=43770597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000787A CL2013000787A1 (es)	2010-09-22	2013-03-21	Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras.

Country Status (18)

Country	Link
US (1)	US8680159B2 (es)
EP (1)	EP2619178A1 (es)
JP (1)	JP2013540750A (es)
KR (1)	KR20140000682A (es)
CN (1)	CN103097354A (es)
AR (1)	AR083167A1 (es)
AU (1)	AU2011304666A1 (es)
BR (1)	BR112013008667A2 (es)
CA (1)	CA2811796A1 (es)
CL (1)	CL2013000787A1 (es)
CO (1)	CO6700838A2 (es)
EA (1)	EA201300388A1 (es)
EC (1)	ECSP13012519A (es)
IL (1)	IL225350A0 (es)
MX (1)	MX2013003309A (es)
PE (1)	PE20131350A1 (es)
TW (1)	TW201217312A (es)
WO (1)	WO2012038081A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201217312A (en) *	2010-09-22	2012-05-01	Gruenenthal Gmbh	Substituted benzamide compounds
US9034874B2 (en) *	2012-07-20	2015-05-19	Novartis Ag	Carbamate/urea derivatives
SG10201802648SA (en) *	2013-04-12	2018-05-30	Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises	Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
WO2014186704A2 (en) *	2013-05-17	2014-11-20	N30 Pharmaceuticals, Inc.	Novel compounds for the treatment of cystic fibrosis
AU2014367781B2 (en) *	2013-12-19	2019-07-04	Eisai R&D Management Co., Ltd.	Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
US9840489B2 (en)	2013-12-20	2017-12-12	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	Piperidine carboxamide compound, preparation method, and usage thereof
AU2015342883B2 (en)	2014-11-06	2020-07-02	Bial - R&D Investments, S.A.	Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en)	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
HRP20240644T1 (hr)	2014-11-06	2024-08-02	Bial-R&D Investments, S.A.	Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
CN105175272A (zh) *	2015-08-31	2015-12-23	吴玲	制备r-5-溴-1-氨基茚满的方法
CA3020305A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en)	2016-04-06	2019-09-18	Lysosomal Therapeutics Inc.	PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
US11192892B2 (en)	2016-04-06	2021-12-07	Bial—R&D Investments, S.A.	Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
SG11201809693SA (en)	2016-05-05	2018-11-29	Lysosomal Therapeutics Inc	SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3452455A4 (en)	2016-05-05	2019-11-13	Lysosomal Therapeutics Inc.	SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN106279114B (zh) *	2016-08-04	2019-01-29	东南大学	一种Taladegib的合成方法
JOP20190156B1 (ar) *	2016-12-23	2023-09-17	Bayer Pharma AG	أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
EP3366683A1 (en) *	2017-02-28	2018-08-29	Acousia Therapeutics GmbH	Cyclic amides, acteamides and ureas useful as potassium channel openers
JP2021515767A (ja)	2018-03-07	2021-06-24	バイエル・アクチエンゲゼルシヤフト	Ｅｒｋ５阻害剤の同定及び使用
CN114933568B (zh) *	2022-05-24	2024-11-26	抚州润泰药业有限公司	一种4,6-二甲基-2-甲磺酰基嘧啶的制备方法
WO2025201439A1 (zh) *	2024-03-28	2025-10-02	上海施江生物科技有限公司	一种芳香环类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU754204B2 (en) *	1998-09-01	2002-11-07	Bristol-Myers Squibb Company	Potassium channel inhibitors and method
US7393852B2 (en) *	2003-06-20	2008-07-01	Amgen Inc.	Piperazine derivatives and methods of use
US20090253908A1 (en)	2004-03-11	2009-10-08	Glaxo Group Limited	Novel m3 muscarinic acetylchoine receptor antagonists
WO2005095387A1 (en)	2004-03-24	2005-10-13	Abbott Laboratories	Tricyclic pyrazole kinase inhibitors
US20070032475A1 (en) *	2005-04-15	2007-02-08	Ye Xiaocong M	Novel compounds useful for bradykinin B1 receptor antagonism
WO2007101007A2 (en)	2006-02-23	2007-09-07	Neurogen Corporation	Aryl sulfonyl heterocycles
WO2007140383A2 (en)	2006-05-30	2007-12-06	Neurogen Corporation	Spirocyclic sulfonamides and related compounds
EP2383267A1 (de)	2006-09-29	2011-11-02	Grünenthal GmbH	Substituierte Sulfonamid-Derivate
EP2086935A1 (de)	2006-10-16	2009-08-12	Grünenthal GmbH	Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
TW201217312A (en) *	2010-09-22	2012-05-01	Gruenenthal Gmbh	Substituted benzamide compounds

2011
- 2011-09-20 TW TW100133690A patent/TW201217312A/zh unknown
- 2011-09-21 CN CN2011800453665A patent/CN103097354A/zh active Pending
- 2011-09-21 MX MX2013003309A patent/MX2013003309A/es not_active Application Discontinuation
- 2011-09-21 BR BR112013008667A patent/BR112013008667A2/pt not_active Application Discontinuation
- 2011-09-21 KR KR1020137010060A patent/KR20140000682A/ko not_active Withdrawn
- 2011-09-21 EP EP11761012.1A patent/EP2619178A1/de not_active Withdrawn
- 2011-09-21 WO PCT/EP2011/004732 patent/WO2012038081A1/de not_active Ceased
- 2011-09-21 JP JP2013529577A patent/JP2013540750A/ja not_active Withdrawn
- 2011-09-21 EA EA201300388A patent/EA201300388A1/ru unknown
- 2011-09-21 AU AU2011304666A patent/AU2011304666A1/en not_active Abandoned
- 2011-09-21 CA CA2811796A patent/CA2811796A1/en not_active Abandoned
- 2011-09-21 PE PE2013000618A patent/PE20131350A1/es not_active Application Discontinuation
- 2011-09-22 US US13/240,598 patent/US8680159B2/en not_active Expired - Fee Related
- 2011-09-23 AR ARP110103474A patent/AR083167A1/es unknown
2013
- 2013-03-20 IL IL225350A patent/IL225350A0/en unknown
- 2013-03-21 CL CL2013000787A patent/CL2013000787A1/es unknown
- 2013-03-21 EC ECSP13012519 patent/ECSP13012519A/es unknown
- 2013-03-22 CO CO13057218A patent/CO6700838A2/es unknown

Also Published As

Publication number	Publication date
US20120071461A1 (en)	2012-03-22
PE20131350A1 (es)	2013-12-08
CA2811796A1 (en)	2012-03-29
TW201217312A (en)	2012-05-01
BR112013008667A2 (pt)	2016-06-21
WO2012038081A1 (de)	2012-03-29
KR20140000682A (ko)	2014-01-03
ECSP13012519A (es)	2013-05-31
EA201300388A1 (ru)	2014-01-30
US8680159B2 (en)	2014-03-25
AR083167A1 (es)	2013-02-06
CO6700838A2 (es)	2013-06-28
EP2619178A1 (de)	2013-07-31
JP2013540750A (ja)	2013-11-07
AU2011304666A1 (en)	2013-05-02
IL225350A0 (en)	2013-06-27
MX2013003309A (es)	2013-04-29
CN103097354A (zh)	2013-05-08

Publication	Publication Date	Title
CL2013000787A1 (es)	2013-09-23	Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras.
SMT201600216B (it)	2016-08-31	Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2014000956A1 (es)	2014-07-18	Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
EP2812004A4 (en)	2015-11-11	COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
SMT201600055B (it)	2016-04-29	Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
EA201270720A1 (ru)	2013-03-29	Модуляторы рецептора андрогенов и их применение
CL2013003598A1 (es)	2014-07-11	Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
IT1400982B1 (it)	2013-07-05	Collirio osmotico trans-epiteliale per la cura del cheratocono.
PT2709604T (pt)	2017-05-17	Canabidivarina para utilização no tratamento de dor neuropática
ITMI20111404A1 (it)	2012-01-29	Supporto per articolazioni umane.
BR112013009589A2 (pt)	2016-07-19	composição de cuidados com o cabelo
BR112015004936A2 (pt)	2017-07-04	composição farmacêutica revestida contendo regorafenib
PL2582366T3 (pl)	2016-04-29	Kombinacja farmaceutyczna do leczenia bólu
CL2015001529A1 (es)	2015-09-25	Compuestos derivados de indol carboxamida, antagonistas del receptor p2x7; composicion farmaceutica y su uso para la prevencion o tratamiento de enfermedades neurodegenerativas y neuroinflamatorias, enfermedades oseas y articulares, enfermedades cardiovaculares, entre otras.
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BRPI0914410A2 (pt)	2016-08-16	composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
EA201600442A1 (ru)	2017-02-28	Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
CL2013000520A1 (es)	2013-08-02	Compuestos derivados de 2-oxi-quinolina-3-carboxamidas sustituidas, moduladores kcnq2/3; composicion farmaceutica; y su uso para el tratamiento y/o porfilaxis del dolor, de preferencia dolor agudo, dolor crónico, dolor neuropatico, dolor visceral. epilepsia, migraña, entre otros.
EP3354254A4 (en)	2019-03-27	SKIN-SHELLING COMPOSITION WITH BETA-MANGOSTINE AS AN ACTIVE SUBSTANCE
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
LT3615014T (lt)	2021-12-27	Vietinė farmacinė kompozicija, apimanti bent amitriptiliną, skirta periferinio neuropatinio skausmo gydymui
CL2013001054A1 (es)	2013-09-27	Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras.
PL3424499T3 (pl)	2020-06-29	Kompozycja farmaceutyczna do leczenia bólu neuropatycznego